Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development

  • S. P. Chellappan
  • A. Giordano
  • P. B. Fisher
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 227)

Abstract

The proliferation of normal cells is regulated by a combination of stimulatory and inhibitory factors that can respond to external signals in a coordinated manner (MacLachlan et al. 1995; Grana and Reddy 1995; Paggi et al. 1996). Various mitogens, growth factors, cytokines, and a host of other agents can perturb the cell cycle machinery eliciting proliferation, differentiation, or apoptosis (Reed et al. 1994; Reddy 1994). Any permanent alteration of the cell cycle-regulatory mechanisms can lead to abnormal proliferation, resulting in neoplasia (Blshor 1987, 1991; Morgan 1992). Such a situation can result following the inactivation of various tumor suppressor proteins, such as Rb and its family members and p53 (Marshall 1991; Cobrinik et al. 1992; Hollingsworth et al. 1993; Ewen 1994; Hooper 1994; Picksley and Lane 1994; Weinberg 1995; Giordano and Kaiser 1996), or by the dominant activation of positive-acting components of the cell cycle machinery, such as the cyclins and cyclin-dependent kinases (CDK) or proto-oncogenes (Pines 1995a, b; Kamb 1995; Bates and Peters 1995).

Keywords

Lymphoma DMSO Proline Oncol Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andres V, Walsh K (1996) Myogenin expression, cell cycle withdrawal and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 132: 657–666PubMedCrossRefGoogle Scholar
  2. Aprelikova O, Xiong Y, Liu ET (1995) Both p16 and p21 families of cyclin-dependent kinase ( CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1270: 18195–18197Google Scholar
  3. Bates S, Peters G (1995) Cyclin DI as a cellular proto-oncogene. Semin Cancer Biol 6: 73–82PubMedCrossRefGoogle Scholar
  4. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H (1990) The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61: 49–59PubMedCrossRefGoogle Scholar
  5. Biggs JR, Kraft AS (1995) Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 75: 509–514Google Scholar
  6. Bishop JM (1987) The molecular genetics of cancer. Science 235: 305–311PubMedCrossRefGoogle Scholar
  7. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235–248PubMedCrossRefGoogle Scholar
  8. Breituran T. Delonick D, Collins S (1980) Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936–2940CrossRefGoogle Scholar
  9. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–557PubMedCrossRefGoogle Scholar
  10. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, Chiorazzi N, Koff A, Huebner K, Croce CM, Giordano A (1995) Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6. PISSLRE and PITALRE and a cdk inhibitor, p27Kipl, to regions involved in human cancer. Cancer Res 55: 1199–1205PubMedGoogle Scholar
  11. Calautti E, Missero C, Stein PL, Ezzell RM, Dotto GP (1995) Fyn tyrosine kinase is involved in keratinocyte differentiation control. Genes Dev 9: 2279–2291PubMedCrossRefGoogle Scholar
  12. Caruso M, Martelli F, Giordano A, Felsani A (1993) Regulation of MyoD gene transcription and protein function by the transforming domains of the adenovirus ElA oncoproteins. Oncogene 8: 267–278PubMedGoogle Scholar
  13. Castresana JS, Rubi MP, Vazquez J, Idoate M, Sober AJ, Seizinger BR, Barnhill RL (1993) Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Intl J Oncol 55: 562–565Google Scholar
  14. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A (1995) Identification of human and mouse p19, anovel CDK4 and CDK6 inhibitor with homology to pl6ink4. Mol Cell Biol 15: 2682–2688PubMedGoogle Scholar
  15. Chellappan SP (1994) The E2F transcription factor: role in cell cycle regulation and differentiation. Mol Cell Diff 2 (3): 201–220Google Scholar
  16. Chen J, Jackson PK, Kireschner MW, Dotta A (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386–388PubMedCrossRefGoogle Scholar
  17. Chen X, Bargonetti J, Prives C (1995) p53, through p21 ( WAFI/CIPI), induces cyclin DI synthesis. Cancer Res 55: 4257–4263PubMedGoogle Scholar
  18. Clark W (1991) Tumor progression and the nature of cancer. Br J Cancer 64: 631–644PubMedCrossRefGoogle Scholar
  19. Clurman BE, Bruns G (1995) Cell cycle and cancer. J Natl Cancer Inst 87: 1499–1501PubMedCrossRefGoogle Scholar
  20. Coats S, Flanagan WM, Nourse J, Roberts JM (1996) Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272: 877–880PubMedCrossRefGoogle Scholar
  21. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA (1992) The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 17: 312–315PubMedCrossRefGoogle Scholar
  22. Collins SJ (1987) The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70: 1233–1244PubMedGoogle Scholar
  23. Collins SJ, Ruscetti FW, Gallagher R, Gallo R (1978) Terminal differentiation of the human promyelocytic leukemia cells induced by dimethylsulfoxide and other polar compounds. Proc Natl Acad Sci USA 75: 2458–2462PubMedCrossRefGoogle Scholar
  24. Coppola JA, Lewis BA, Cole MD (1990) Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. Oncogene 5: 1731–1733PubMedGoogle Scholar
  25. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363: 595–602PubMedCrossRefGoogle Scholar
  26. Del Sal G, Murphy M, Ruaro EM, Lazarevic D, Levine AJ, Schneider C (1996) Cyclin D1 and p21 /wafl are both involved in p53 growth suppression. Oncogene 12: 177–185PubMedGoogle Scholar
  27. Desai D, Wessling HC, Fisher RP, Morgan DO (1995) Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol 15: 345–350PubMedGoogle Scholar
  28. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21c1Pi/WAF1 undergo normal development, but are defective in GI checkpoint control. Cell 82: 675–684PubMedCrossRefGoogle Scholar
  29. DiGiuseppe JA, Redstone MS, Yeo CJ, Kern SE, Hruban RH (1995) p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pacreatic carcinoma. Am J Pathol 147: 884–888Google Scholar
  30. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215–221PubMedCrossRefGoogle Scholar
  31. Dover R, Wright NA (1991) The cell proliferation kinetics of the epidermis. In: Goldsmith LA (ed) Physiology, biochemistry, and molecular biology of the skin. Oxford University Press, New York, pp 239–265Google Scholar
  32. Dracopoli NC, Sam B, Fountain JW, Schartl M (1992) A homolog of the Xiphophorus melanoma-inducing locus Xmrk maps to 6q27 a region frequently involved in rearrangements and deletions in human melanomas. Abstr Am J Hum Genet 54: A51Google Scholar
  33. Dulie V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced GI arrest. Cell 76: 1013–1023Google Scholar
  34. Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ (1995) A new type of p16INK4/MTSI gene transcript expressed in B-cell malignancies. Oncogene 11: 21–29PubMedGoogle Scholar
  35. Duro D, Bernard O, Della Valle V, Leblanc T, Berger R, Larsen CJ (1996) Inactivation of the PI6INK4/ MTSI gene by a chromosome translocation t(9;14)(p21–22;811) in an acute lymphoblastic leukemia of B-cell type. Cancer Res 56: 848–854PubMedGoogle Scholar
  36. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart JD, Marks JR (1994) Transforming growth factor ßl can induce CIPI/WAFT expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Diff 5: 1301–1307PubMedGoogle Scholar
  37. EI-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler, KW, Vogelstein B (1993) WAFT, a potential mediator of p53 tumor suppression. Cell 75: 817–825CrossRefGoogle Scholar
  38. Elledge SJ, Harper JW (1994) Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847–852PubMedCrossRefGoogle Scholar
  39. Ewen ME (1994) The cell cycle and the retinoblastoma protein family. Cancer Metastas Reviews 13: 45–66CrossRefGoogle Scholar
  40. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM (1993) Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487–497PubMedCrossRefGoogle Scholar
  41. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kipl)-deficient mice. Cell 85: 733–744PubMedCrossRefGoogle Scholar
  42. Filvaroff E, Stern DF, Dotto GP (1990) Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiation. Mol Cell Biol 10: 1164–1173PubMedGoogle Scholar
  43. Firpo EJ, Koff A, Solomon MJ, Roberts JM (1994) Inactivation of cdk2 inhibitor during interleukin 2-induced proliferation of human T-lymphocytes. Mol Cell Biol 14: 4889–4901PubMedGoogle Scholar
  44. Fisher PB, Schachter D, Abbott RE, Callaham MF, Huberman E (1984) Membrane lipid dynamics in human promyelocytic leukemia cells sensitive and resistant to 12-O-tetradecanoyl-phorbol-l3-acetate induction of differentiation. Cancer Res 44: 5550–5554PubMedGoogle Scholar
  45. Fisher PB, Prignoli DR, Hermo H Jr, Weinstein IB, Pestka S (1985) Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. J Interferon Res 5: 11–22PubMedCrossRefGoogle Scholar
  46. Fisher RP, Morgan DO (1994) A novel cyclin associates MO15/CDK7 to form the CDK-activating kinase. Cell 78: 713–724PubMedCrossRefGoogle Scholar
  47. Flores-Rozas H, Kelman Z, Dean FB, Pan Z, Harper WJ, Elledge SJ, O’Donnell M, Hurwitz J (1994) Cdk- interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase and holoenzyme. Proc Natl Acad Sci USA 91:8655–8659PubMedCrossRefGoogle Scholar
  48. Fountain JW, Bale SJ, Housman DE, Dracopoli NC (1990) Genetics of melanoma. Cancer Sury 9: 645–671Google Scholar
  49. Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Fisher PB, Chellappan SP, Grant S (1997) Effects of antisense p21 (WAF1/CIPI/MDA-6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia 11: 504–513PubMedCrossRefGoogle Scholar
  50. Galktionov K, Jesus C, Beach D (1995) Raf-1 interaction with Cdc25 phosphatase ties mitogenic signaling to cell cycle activation. Genes Dev 9: 1046–1058CrossRefGoogle Scholar
  51. Gautier J, Solomon M, Booher R, Bazan J, Kirshner M (1991) Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67: 197–211PubMedCrossRefGoogle Scholar
  52. Giordano A, Kaiser H (1996) The retinoblastoma gene: its role in cell cycle and cancer. In Vivo, 10: 223–228Google Scholar
  53. Goldstein S (1990) Replicative senescence: the human fibroblast comes of age. Science 249: 1129–1133PubMedCrossRefGoogle Scholar
  54. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM (1995) Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531–4535PubMedGoogle Scholar
  55. Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors ( CKIs ). Oncogene 11: 211–219PubMedGoogle Scholar
  56. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878PubMedGoogle Scholar
  57. Gu W, Schneider JW, Condorelli G, Nadal-Ginard B (1993) Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72: 309–324PubMedCrossRefGoogle Scholar
  58. Gu Y, Rosenblatt J, Morgan DO (1992) Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 11. 3995–4005PubMedGoogle Scholar
  59. Gu Y, Turck CW, Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20 K regulatory subunit. Nature 366: 707–710PubMedCrossRefGoogle Scholar
  60. Guan K, Jenkins CW, Li Y. Nichols MA, Wu X, O’Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16INK/MTSI and pl4INK4/MTS2-related CDK6 inhibitor, correlates with wild-type RB function. Genes Dev 8: 2939–2952PubMedCrossRefGoogle Scholar
  61. Guan X, Meltzer PS, Can J, Trent, JM (1992) Rapid generation of region-specific genomic clones by chromosome microdissection: isolation of DNA from a region frequently deleted in malignant melanoma. Genomics 14: 680–684PubMedCrossRefGoogle Scholar
  62. Guo K, Wang J, Andres V, Smith RC, Walsh K (1995) MyoD-induced expression of p2I inhibits cyclin- dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15: 3823–3829PubMedGoogle Scholar
  63. Halevy O. Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018–1021PubMedCrossRefGoogle Scholar
  64. Hall M, Bates S, Peters G (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: pl5 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581–1588PubMedGoogle Scholar
  65. Hannon GJ, Beach D (1994) pl5INK4b is a potential effector of cell cycle arrest mediated by TGF13. Nature 371: 257–261Google Scholar
  66. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge Si (1993) The p21 CDK-interacting protein CIPI is a potential inhibitor of GI cyclin-dependent kinases. Cell 75: 805–816PubMedCrossRefGoogle Scholar
  67. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821–1828PubMedCrossRefGoogle Scholar
  68. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA (1994) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet 5: 225–229CrossRefGoogle Scholar
  69. Hebert J, Cayuela JM, Berkeley J, Sigaux F (1994) Candidate tumor-suppressor genes MTSI (p16INK4A) and MTS2 (p151NK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84: 4038–4044PubMedGoogle Scholar
  70. Hengst L, Reed SI (1996) Translational control of p27Kipl accumulation during the cell cycle. Science 271: 1861–1864PubMedCrossRefGoogle Scholar
  71. Hennings H, Micahel D, Cheng C, Steinert P, Holbrook K, Yuspa SH (1980) Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 19: 245–254PubMedCrossRefGoogle Scholar
  72. Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D (1995) Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21wAFr/CIPI /SDI Oncogene 11: 1409–1415Google Scholar
  73. Herlyn M (1990) Human melanoma: development and progression. Cancer Metastas Rev 9: 101–112CrossRefGoogle Scholar
  74. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ (1995) Novel INK4 proteins, p19 and pIll, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15: 2672–2681PubMedGoogle Scholar
  75. Hollenstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science, 253: 49–53Google Scholar
  76. Hollingsworth RJ, Hensey CE, Lee WH (1993) Retinoblastoma protein and the cell cycle. Curr Opin Genet Dev 3: 55–62PubMedCrossRefGoogle Scholar
  77. Hooper ML (1994) The role of the p53 and Rb-I genes in cancer, development and apoptosis. J Cell Sci Suppl 18: 13–17PubMedGoogle Scholar
  78. Horowitz JM, Udvadia AJ, (1995) Regulation of transcription by the retinoblastoma (Rb) protein. Mol Cell Diff 3 (4): 275–314Google Scholar
  79. Huberman E, Callaham MF (1979) Induction of terminal differentiation in human promyeolcytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76: 1293–1297PubMedCrossRefGoogle Scholar
  80. Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573–582PubMedCrossRefGoogle Scholar
  81. Jacks T, Fazeli A, Schmitt EM, Bronson RY, Goodell MA, Weinberg RA (1992) Effects of an Rh mutation in the mouse. Nature 359: 295–300PubMedCrossRefGoogle Scholar
  82. Jacks T, Remington L, Wiliams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7PubMedCrossRefGoogle Scholar
  83. Jiang H. Fisher PB (1993) Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol Cell Diff 1 (3): 285–299Google Scholar
  84. Jiang H, Su Z-Z, Boyd J, Fisher PB (1993) Gene expression changes associated with reversible growth suppression and the induction of terminal differentiation in human melanoma cells. Mol Cell Dill 1 (1): 4l - 66Google Scholar
  85. Jiang H, Lin J, Fisher PB (1994a) A molecular definition of terminal cell differentiation in human melanoma cells. Mol Cell Diff 2 (3): 221–239Google Scholar
  86. Jiang H, Lin J, Su Z-Z, Collart FR, Huberman E, Fisher PB (1994b) Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAFI/CIPI, expression in the absence of p53. Oncogene 9: 3389–3396Google Scholar
  87. Jiang H, Lin JJ, Su Z-Z, Goldstein NI, Fisher PB (1995a) Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477–2486PubMedGoogle Scholar
  88. Jiang H, Lin J, Su Z-Z, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB, (1995b) The melanoma differentiation associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10: 1855–1864PubMedGoogle Scholar
  89. Jiang H, Lin J, Young S-M, Goldstein NI, Waxman S, Davilla V, Chellappan SP, Fisher PB (1995e) Cell cycle gene expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate. Oncogene 11: 1179–1189PubMedGoogle Scholar
  90. Jiang H, Lin J, Su Z-Z, Fisher PB (1996a) The melanoma differentiation associated gene-6 (mda-6), which encodes the cyclin-dependent kinase inhibitor p21, may function as a negative regulator of human melanoma growth and progression. Mol Cell Diff 4 (1): 67–89Google Scholar
  91. Jiang H, Su Z-Z, Lin JJ, Goldstein NI, Young CSH, Fisher PB (1996b) The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 93: 9160–9165PubMedCrossRefGoogle Scholar
  92. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, Okayama H (1994) Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13: 1549–1556PubMedGoogle Scholar
  93. Kacker RK, Giovanella BC, Pathak S (1990) Consistent karyotypic abnormalities in human malignant melanomas. Anticancer Res 10: 859–872PubMedGoogle Scholar
  94. Kamb A (1995) Cell-cycle regulators and cancer. Trends Genet 11: 136–140PubMedCrossRefGoogle Scholar
  95. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994) A cell cycle regulator involved in genesis of many tumor types. Science 264: 436–440PubMedCrossRefGoogle Scholar
  96. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331–342PubMedCrossRefGoogle Scholar
  97. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ (1994a) Cyclic AMP-induced GI phase arrest mediated by an inhibitor (p27Kipl) of cyclin-dependent kinase 4 activation. Cell 79: 487–496PubMedCrossRefGoogle Scholar
  98. Kato JY, Matsuoka M, Strom DK, Sherr CJ (1994b) Regulation of cyclin D-dependent kinase 4 (cdk4)–by cdk4-activating kinase. Mol Cell Biol 14: 2713–2721PubMedGoogle Scholar
  99. Kerbel RS (1990) Growth dominance and the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55: 87–132PubMedCrossRefGoogle Scholar
  100. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721–732PubMedCrossRefGoogle Scholar
  101. Kobayashi H, Man S, MacDougall JR, Graham CH, Lu C, Kerbel RS (1994) Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype. Am J Pathol 144: 776–786PubMedGoogle Scholar
  102. Koff A, Ohtuski M, Polyak K, Roberts JM, Massague J (1993) Negative regulation of GI in mammalian cells: Inhibition of cyclin E-dependent kinase by TGFß. Science 260: 536–539Google Scholar
  103. Koh J, Enders GH, Dynlacht BD, Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–510PubMedCrossRefGoogle Scholar
  104. Laiho M, DeCaprio J, Ludlow J, Livingston DM, Massague J (1990) Growth suppression by TGFß linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175–185PubMedCrossRefGoogle Scholar
  105. Lassar AB, Skapek SX, Novitch B (1994) Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 6: 788–794PubMedCrossRefGoogle Scholar
  106. Lee EY-HP, Chang CY, Hu N, Wang Y-CJ, Lai C-C, Herrup K, Lee WH, Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature 359: 288–294PubMedCrossRefGoogle Scholar
  107. Lee MHJ, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639–649PubMedCrossRefGoogle Scholar
  108. Lee MH, Nikolic M, Baptista CA, Lai E, Tsai LH, Massague J (1996) The brain-specific activator p35 allows CdkS to escape inhibition by p27KIPI in neurons. Proc Natl Acad Sci USA 93: 3259–3263PubMedCrossRefGoogle Scholar
  109. Li R, Waga S, Hannon GJ, Beach D, Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534–537PubMedCrossRefGoogle Scholar
  110. Li S, MacLachlan TK, De Luca A, Claudio PP, Condorelli G, Giordano A (1995) The cdc-2-related PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res 55: 3992–3996PubMedGoogle Scholar
  111. Li Y, Jenkins CW, Nichols MA, Xiong Y (1994) Cell cycle expression and p53 regulation of the cyclindependent kinase inhibitor p21. Oncogene 9: 2261–2268PubMedGoogle Scholar
  112. Liotta LA, Steeg PG, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336PubMedCrossRefGoogle Scholar
  113. Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142–153PubMedCrossRefGoogle Scholar
  114. Loganzo F Jr, Nabeya Y, Maslak P, Albino AP (1994) Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: implications for melanoma development. Mol Cell Diff 2 (1): 23–43Google Scholar
  115. Lotem J, Sachs L (1979) Regulation of normal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc Natl Acad Sci USA 76: 5158–5162PubMedCrossRefGoogle Scholar
  116. Lu C, Kerbel RS (1994) Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol 6: 212–220PubMedCrossRefGoogle Scholar
  117. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retino-blastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–506PubMedCrossRefGoogle Scholar
  118. Luo Y, Hurwitz J, Massague, J (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Kip1. Nature 375: 159–161PubMedCrossRefGoogle Scholar
  119. MacDougall JR, Kobayashi H, Kerbel RS (1993) Responsiveness of normal/dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-ß. Mol Cell Diff 1 (1): 21–40Google Scholar
  120. MacLachlan TK, Sang N, Giordano A (1995) Cyclins, cyclin-dependent kinases and Cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Express 5 (2): 127–156Google Scholar
  121. Macleod FF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T (1995) p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev 9: 935–944Google Scholar
  122. MacJohnson DD, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith JR (1994) Evidence for a p53-independent pathway for upregulation of SDI1/CIPI/WAF1/p21 RNA in human cells. Mol Carcinog 11: 59–64CrossRefGoogle Scholar
  123. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML (1996) Inactivation of p27Kipl by the viral EIA oncoprotein in TGFbeta-treated cells. Nature 380: 262–265PubMedCrossRefGoogle Scholar
  124. Mangelsdorf DJ, Pike JW, Haussier MR (1984) I25-dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 98: 391–398PubMedCrossRefGoogle Scholar
  125. Massague J, Polyak K (1995) Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 5: 91–96PubMedCrossRefGoogle Scholar
  126. Marshall CJ (1991) Tumor suppressor genes. Cell 64: 313–326PubMedCrossRefGoogle Scholar
  127. Matsuoka M, Kato JY, Fisher RP, Morgan DO, Sherr CJ (1994) Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol 14: 7265–7275PubMedGoogle Scholar
  128. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9(6):650–662PubMedCrossRefGoogle Scholar
  129. Matsushime H, Roussel M, Ashmun R, Sherr CJ (1991) Colony stimulating factor 1 regulates novel cyclins during the GI phase of the cell cycle. Cell 65: 701–713PubMedCrossRefGoogle Scholar
  130. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066–2076PubMedGoogle Scholar
  131. McCarthy DM, San Miguel J, Freake HC, Green PM, Zola H, Catowsky D, Goldman.1 (1983) 1,25dihydroxyvitamin D3 inhibits the proliferation of human promyelocytic leukemia cell line (HL-60) cells and induces monocyte-macrophage differentiation in HL-60 and normal bone marrow cells. Leuk Res 7: 51–55Google Scholar
  132. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAFT/CIPI by a p53-independent pathway. Cancer Res 54: 3391–3395PubMedGoogle Scholar
  133. Miele ME, Robertson G, Lee J-H, Coleman A, McGary CT, Fisher PB, Lugo TG, Welch DR (1996) Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosome 1 or 6. Mol Carcinog 15: 284–299PubMedCrossRefGoogle Scholar
  134. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto PG (1995) Involvement of the cell-cycle inhibitor Cipl/Wafl and the EIA-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 92: 5451–5455PubMedCrossRefGoogle Scholar
  135. Missero M, Dotto GP (1996) p21wAFUCIPI and terminal differentiation control of normal epithelia. Mol Cell Diff 4(1):1–16Google Scholar
  136. Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, Suda T (1981) P25-dihydroxyvitaroin D; induces differentiation of human myeloid leukemia cells. Biochcm Bipophys Res Commun 102: 937–943CrossRefGoogle Scholar
  137. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J (1994) Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 9: 1455–1459PubMedGoogle Scholar
  138. Morgan DO (1992) Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev 2:33–37 Morgan DO (1995) Principles of CDK regulation. Nature 374: 131–134Google Scholar
  139. Morgan DO (1996) Under arrest at atomic resolution. Nature 382: 295–296PubMedCrossRefGoogle Scholar
  140. Morgan DO, De Bondt HL (1994) Protein kinase regulation: insights from crystal structure analysis. Curr Opin Cell Biol 6 (2): 239–246PubMedCrossRefGoogle Scholar
  141. Murao S-I, Gemmell MA, Callahan MF, Anderson NL, Huberman E (1983) Control of macrophage cell differentiation in human promyelocytic HL-60 leukemia cells by 1,25-dihydroxyvitamin D3 and phorbol-l2-myristate-13-acetate. Cancer Res 43: 4989–4996PubMedGoogle Scholar
  142. Nakanishi M, Robetorge RS, Adami GR, Pereira-Smith OM, Smith JR (1995) Identification of the active region of the DNA synthesis inhibitory gene p21IIPI/wAF. EMBO J 14: 555–563PubMedGoogle Scholar
  143. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K (1996) Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707–720PubMedCrossRefGoogle Scholar
  144. Nevins JR (1992) E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424–429PubMedCrossRefGoogle Scholar
  145. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin dependent kinase 4 inhibitor gene in multiple human cancers. Nature 368: 753–756PubMedCrossRefGoogle Scholar
  146. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90–98PubMedCrossRefGoogle Scholar
  147. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree J, Roberts JM (1994) Interleukin 2-mediated elimination of p27KIPl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570–573PubMedCrossRefGoogle Scholar
  148. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC (1994) Mutations and altered expression p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045–11049PubMedCrossRefGoogle Scholar
  149. Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd Vi, Lahti JM, Sherr CJ, Downing JR (1995a) Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 29: 623–630PubMedCrossRefGoogle Scholar
  150. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui C-H, Sherr CJ, Beach D, Look AT, Downing JR (1995b) Frequent deletion of pl6INK4a/MTSI and pl5lNK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85: 2321–2330PubMedGoogle Scholar
  151. Olson EN, Klein WH (1994) bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev 8: 1–8Google Scholar
  152. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682–685PubMedCrossRefGoogle Scholar
  153. Paggi MG, Baldi A, Bonetto F, Giordano A (1996) The retinoblastoma protein family in cell cycle and cancer. J Cell Biochem 62: 418–430PubMedCrossRefGoogle Scholar
  154. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ (1995) p53-independent expression of p21cIPI in muscle and other terminally differentiating cells. Science 267: 1024–1027Google Scholar
  155. Parry D, Bates S, Mann DJ, Peters G (1995) Lack of cyclin D-Cdk complexes in Rh-negative cells correlates with high levels of p16INK4/MTSI tumour suppressor gene product. EMBO J 14 (3): 503–511PubMedGoogle Scholar
  156. Pathak S, Drwinga HL, Hsu TC (1983) Involvement of chromosome 6 in rearrangements in human malignant melanoma. Cancer Genet Cytotgenet 36: 573–579CrossRefGoogle Scholar
  157. Picksley SM, Lane DP (1994) p53 and Rb: their cellular roles. Curr Opin Cell Biol 6: 853–858Google Scholar
  158. Pientenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask III, Roberts JM, Kinzler KW, Rowley JD, Vogelstein B (1995) Assignment of the human p27Kipl gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206–1210Google Scholar
  159. Pines J (1995a) Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res 66:181–212PubMedCrossRefGoogle Scholar
  160. Pines J (1995b) Cyclins, CDKs and cancer. Semin Cancer Biol 6: 63–72PubMedCrossRefGoogle Scholar
  161. Pines J (1995c) Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 308: 697–711PubMedGoogle Scholar
  162. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994a) p27KipI, a cyclin- Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9–22Google Scholar
  163. Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague,l (1994b) Cloning of p27KIPI, a cyclin-dependent-kinase inhibitior and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–76Google Scholar
  164. Ponce-Castaneda MV, Lee MH, Latres E, Polyack K, Lacombe L, Montgomery K, Mathew S, Krauter K, Massague J, Cordon-Cardo C (1995) p27: chromosomal mapping to 12p12 and absence of mutations in human tumors. Cancer Res 55: 1211–1214Google Scholar
  165. Poon RY, Hunter T (1995) Cell regulation. Innocent bystanders or chosen collaborators? Curr Biol 5: 1243–1247PubMedCrossRefGoogle Scholar
  166. Poon RY, Yamashita K, Adamczewski JP, Hunt T, Shuttleworth J (1993) The cdc2-related protein p40MOI5 is the catalytic subunit of a protein kinase that can activate cdc2. EMBO J 12(8):3123–3132PubMedGoogle Scholar
  167. Poon RY, Toyoshima H, Hunter T (1995) Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 6: 1197–1213PubMedGoogle Scholar
  168. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995a) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000PubMedCrossRefGoogle Scholar
  169. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M (1995b) Cloning and characterization of murine p16INK4a and pI5INK4b genes. Oncogene 11: 635–645PubMedGoogle Scholar
  170. Rao SS, Chu C, Kohtz DS (1994) Ectopic expression of cyclin Dl prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 14: 5259–5267PubMedGoogle Scholar
  171. Reddy GP (1994) Cell cycle: regulatory events in GI-S transition of mammalian cells. J Cell Biochem 54: 379–386PubMedCrossRefGoogle Scholar
  172. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J (1994) GI control in mammalian cells. J Cell Sci Suppl 18: 69–73PubMedGoogle Scholar
  173. Reynisdottir I, Polyak K, Iavarone A, Massague J (1995) Kip/Cil) and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831–1845PubMedCrossRefGoogle Scholar
  174. Robetorye RS, Nakanishi M, Venable SF, Pereira-Smith OM, Smith JR (1996) Regulation of p2lsd~i~c~n~w.~nh„d“-6 and expression of other cyclin-dependent kinase inhibitors in senescent cell. Mol Cell Diff4(1): 113–126Google Scholar
  175. Rovera G, Santoli D, Damsky C (1979) Human promyeolcytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 76: 2779–2783PubMedCrossRefGoogle Scholar
  176. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP (1996) Crystal structure of the p27Kipl cyclin-dependent-kinase inhibitor bound to the cyclin A-cdk2 complex. Nature 382: 325–331PubMedCrossRefGoogle Scholar
  177. Sang N, Baldi A, Giordano A (1995) The roles of tumor suppressors pRb and p53 in cell proliferation and cancer. Mol Cell Diff 3 (1): 1–29Google Scholar
  178. Schneider JW, Gu W, Zhu L, Mandavi V, Nadal-Ginard B (1995) Reversal of terminal differentiation meidated by p107 in Rb-/- muscle cells. Science 264: 1467–1471CrossRefGoogle Scholar
  179. Schwaller J, Koeffler HP, Niklaus G, Loetscher P, Magd S, Fey MF, Tobler A (1995) Posttranscriptional stabilization underlies p53-independent induction of p21/WAFT/CIP1/SDI I in differentiating human leukemic cells. J Clin Invest 95: 973–979PubMedCrossRefGoogle Scholar
  180. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclinD-cdk4. Nature 366: 704–707PubMedCrossRefGoogle Scholar
  181. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D (1995) Inhibition of ras-induced proliferation and cellular transformation by pl6INK4. Science 267: 249–252PubMedCrossRefGoogle Scholar
  182. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of INK4a locus in tumor suppression and cell mortality. Cell 85: 27–37PubMedCrossRefGoogle Scholar
  183. Sheikh MS, Li X-S, Chen J-C, Shao Z-M, Ordonez JV, Fontana JA (1994) Mechanisms of regulation of WAF1/CipI gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407–3415PubMedGoogle Scholar
  184. Sherr CJ (1993) Mammalian GI cyclins. Cell 73: 1059–1065PubMedCrossRefGoogle Scholar
  185. Sherr CJ (1994a) GI phase progression: cycling on cue. Cell 79: 551–555PubMedCrossRefGoogle Scholar
  186. Sherr CJ (1994b) Growth-factor-regulated GI cyclins. Stem Cells 12[Suppl] 1: 47–55Google Scholar
  187. Sherr CJ (1995) D-type cyclins. Trends Biochem. Sci 20: 187–190Google Scholar
  188. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian Gicyclin-dependent kinases. Genes Dev 9: 1149–1163PubMedCrossRefGoogle Scholar
  189. Sherr CJ, Kato J, Quelle DE, Matsuoka M, Roussel MF (1994) D-type cyclins and their cyclin-dependent kinases: GI phase integrators of the mitogenic response. Cold Spring Harb Symp Quant Biol 59: 1 1–19Google Scholar
  190. Shiekhattar R, Mermelstein F, Fisher, RP, Drapkin R, Dynlacht B, Wessling HC, Morgan DO, Reinberg D (1995) Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 374: 283–287PubMedCrossRefGoogle Scholar
  191. Shivji MKK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ (1994) CipI inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr Biol 4: 1062–1068PubMedCrossRefGoogle Scholar
  192. Skapek SX, Rhee J, Spicer DB, Lassar AB (1995) Inhibition of myogenic differentiation in proliferating myoblasts by cyclin DI-dependent kinase. Science 267: 1022–1027PubMedCrossRefGoogle Scholar
  193. Smith JR, Pereira-Smith OM (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science 273: 63–67PubMedCrossRefGoogle Scholar
  194. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME (1994) Induction of p21 (WAFT/CIP1) during differentiation. Oncogene 9: 3389–3396PubMedGoogle Scholar
  195. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the PI6 (MTS1) locus. Cancer Res 55: 2988–2994PubMedGoogle Scholar
  196. Su Z-Z, Austin VA, Zimmer SG, Fisher PB (1993) Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-rastransformed cloned rat embryo fibroblast cells. Oncogene 8: 1211–1219PubMedGoogle Scholar
  197. Su Z-Z, Yemul S, Estabrook A, Zimmer SG, Friedman RM, Fisher PB (1995) Transcriptional switching model for the regulation of tumorigenesis and metastasis by the Ha-ras oncogene: transcriptional changes in the Ha-ras tumor suppressor gene lysyl oxidase. Intl J Oncology 7: 1279–1284Google Scholar
  198. Tam SW, Shay JW, Pagano M (1994) Differential expression and cell cycle regulation of the cyclin dependent kinase 4 inhibitior pI6INK4. Cancer Res 54: 5816–5820PubMedGoogle Scholar
  199. Toyoshima H, Hunter T (1994) p27, a novel inhibitior of Gl-cyclin-cdk protein kinase activity is related to p21. Cell 78: 67–74Google Scholar
  200. Trent JM (1991) Cytogenetics of human malignant melanoma. Cancer Metastas Rev 10: 103–113CrossRefGoogle Scholar
  201. Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, Araujo DE, Witkowski CM, Nagle RB (1990) Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568–571PubMedCrossRefGoogle Scholar
  202. lJeki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150–153Google Scholar
  203. Volkenandt M, Schlegel U, Manus DM, Albino AP (1991) Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 4: 35–40PubMedCrossRefGoogle Scholar
  204. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574–578PubMedCrossRefGoogle Scholar
  205. Walsch K, Guo K, Wang J, Andres V (1996) p21 Regulation and function during myogenesis. Mol Cell Diff 4(I):17–31Google Scholar
  206. Wang J, Walsh K (1996) Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273: 359–361PubMedCrossRefGoogle Scholar
  207. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323–330PubMedCrossRefGoogle Scholar
  208. Weintraub H (1993) The MyoD family and myogenesis: redundancy, networks and thresholds. Cell 75: 1241–1244PubMedCrossRefGoogle Scholar
  209. Welch DR, Rieber M (1996) Is p21 WAFT a suppressor of malignant melanoma metastasis? Mol Cell Diff 4(1):91–11lGoogle Scholar
  210. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Gilmore LB, Seftor REB, Nakajima M, Hendrix MJC (1991) Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47: 227–237PubMedCrossRefGoogle Scholar
  211. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Weissman BE, Stanbridge EJ (1994) Microcellmediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9: 255–262PubMedGoogle Scholar
  212. Whyte P (1995) The retinoblastoma protein and its relatives. Semin Cancer Biol 6: 83–90PubMedCrossRefGoogle Scholar
  213. Williams BO, Schmitt, EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T (1994a) Extensive contribution of Rb deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 13: 4251–4259PubMedGoogle Scholar
  214. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T (1994) Cooperative tumorigenic effects of germ-line mutations in Rb and p53. Nature Genet 7: 480–484PubMedCrossRefGoogle Scholar
  215. Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T (1996) Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Genes Dev 10: 245–260PubMedCrossRefGoogle Scholar
  216. Xiong Y, Zhang H, Beach D (1992) D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505–514PubMedCrossRefGoogle Scholar
  217. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993a) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704Google Scholar
  218. Xiong Y, Zhang H, Beach D (1993b) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7: 1572–1583PubMedCrossRefGoogle Scholar
  219. Yang Z-Y, Perkins ND, Ohno O, Nabel EG, Nabel GJ (1995) The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1: 1052–1056PubMedCrossRefGoogle Scholar
  220. Yuan W, Condorelli G, Caruso M, Felsani A, Giordano A (1996) Human p300 protein is a coactivator for the transcription factor MyoD. J Biol Chem 271: 9009–9013PubMedCrossRefGoogle Scholar
  221. Zakut R, Givol D (1995) The tumor suppressor function of p21 is contained in its N-terminal half (`half-WAF’). Oncogene 11: 393–395PubMedGoogle Scholar
  222. Zhang H, Xiong Y, Beach D (1993) Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897–906PubMedGoogle Scholar
  223. Zhang H, Hannon GJ, Beach D (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750–1758PubMedCrossRefGoogle Scholar
  224. Zhang W, Grasso L, McClain CD, Gambel AM, Cham Y, Travali S, Deisseroth AB, Mercer WE (1995) p53-independent induction of WAFI/CIP] in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668–674PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • S. P. Chellappan
    • 1
  • A. Giordano
    • 3
  • P. B. Fisher
    • 1
    • 2
  1. 1.Department of Pathology, Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons of Columbia UniversityNew YorkUSA
  2. 2.Department of Urology, Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons of Columbia UniversityNew YorkUSA
  3. 3.Department of Pathology, Anatomy and Cell Biology, Kimmel Cancer InstituteThomas Jefferson University, Sbarro Institute for Cancer Research and Molecular MedicinePhiladelphiaUSA

Personalised recommendations